ArticleLife (Basel, Switzerland)2026
Bleeding and Thrombotic Risk in Cirrhosis: Hemostatic Profiles from a Single-Center Experience.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesCirrhosis is characterized by a fragile and unstable hemostatic balance, predisposing patients to both hemorrhagic and thrombotic complications, particularly in the context of chronic liver disease (CLD). This dual risk presents significant challenges for clinical management and complicates therapeutic decisions. The objective of this study was to evaluate coagulation profiles in cirrhotic patients and their association with bleeding and thrombotic events, with the aim of identifying predictors of hemostatic complications.
methodsA retrospective study was conducted on patients with cirrhosis admitted to a tertiary liver transplant center between February 2022 and March 2024. Inclusion criteria required the availability of extended coagulation data in medical records. Demographic, clinical, and laboratory parameters were collected and analyzed to assess associations with thrombotic events and upper gastrointestinal bleeding (UGIB).
resultsFifty-nine patients met the inclusion criteria (mean age 53.4 ± 10.3 years), of whom 62.7% were male. UGIB occurred in 18.6% of patients, thrombotic events in 20.3%, and portal vein thrombosis in 16.9%. Routine coagulation parameters, including international normalized ratio (INR) and activated partial thromboplastin time (APTT), did not demonstrate significant predictive value for either bleeding or thrombotic events.
conclusionsPatients with cirrhosis are simultaneously at risk for both bleeding and thrombosis, reflecting the fragile and complex nature of hemostatic regulation in advanced liver disease (ALD). Standard laboratory coagulation tests are inadequate for accurate risk stratification in this setting. These findings highlight the limitations of conventional coagulation tests and support the need for further studies evaluating advanced hemostatic assessment tools in patients with cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.